A method of producing biologically active human acidic fibroblast growth factor and its use in promoting angiogenesis
CA 2419338 A1 · Owner: Slavchenko, Iryna Yu. · Inventors: Chernykh, Svitlana I.; Slavchenko, Iryna Yu.; Stegmann, Thomas J.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The gene of human acidic fibroblast growth factor 155 (haFGF 155) has been obtained by chemical synthesis. The nucleotide sequence of haFGF 155 gene has been deduced on the basis of haFGF 155 amino acid sequence as described in the literature. The amino acid sequence of the synthesized haFGF 155 does not differ from those described in the literature. The nucleotide sequence of haFGF gene differs from those described previously. For chemical synthesis of haFGF 155 gene, codons were used which are the ones most often used by E. coli in highly expressed E. coli proteins. A plasmid with haFGF 155 (phaFGF 155) gene was obtained and was used to transform E. coli. Production of haFGF 154 …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed August 15, 2001. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended August 15, 2021.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by August 15, 2023.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.